ClinicalTrials.gg
CompletedNCT06963476Updated Sep 29, 2026

rTMS as Add on Treatment for Substance Use Disorders

An interventional study of repetitive transcranial magnetic stimulation (rTMS) for AUD and repetitive transcranial magnetic stimulation (rTMS) for OUD in Opioid Use and Alcohol Use Disorder, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

How we know

Updated Sep 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies in Alcoholism by Yale University — 19 open to participants now, 22 under way, 1 of them phase 3. Alcoholism · Yale University.

Enrollment
56th of 85
47 · median 64
Started
2025
with 3 others
No phase
29 of 94
6 open now
Registered
83rd of 94
by date

Among the 94 studies in Alcoholism by Yale University, this one is the 56th largest by enrollment of the 85 interventional ones that give a count, is one of 4 that started in 2025, is one of 29 with no phase, and was the 83rd registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

19 of the 94 studies in Alcoholism by Yale University are open now, in 2 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Alcoholism by Yale University, or all of them as a file.
02

Study summary

This pilot study is designed to test feasibility and superiority of rTMS types and target locations for the optimal rTMS intervention for individuals seeking treatment for Alcohol Use Disorder (AUD) or Opioid Use Disorder (OUD).

The critical questions this study seeks to answer are: which rTMS type applied to l-dlPFC in OUD participants will induce the greatest reduction of opioid use post-treatment? Is inhibitory rTMS applied to medial prefrontal cortex (mPFC) more effective than excitatory rTMS applied to l-dlPFC at reducing alcohol use post treatment in AUD participants?

Read the detailed description

Aim 1: To assess feasibility of applying rTMS within a residential treatment center. Feasibility will be assessed by 1) recruitment of sufficient numbers of AUD and OUD participants; 2) completion of the rTMS intervention; 3) retention of follow-up at the 4-week interval.

Aim 2: To assess superiority of mPFC cTBS compared to l-dlPFC iTBS to reduce alcohol use in AUD patients post-treatment. Superiority will be assessed by evaluating 1) treatment engagement at the 4-week interval (e.g., number of prescribed AUD treatments addended); 2) reduction of drinks/day post-treatment, compared to pre-treatment; 3) reduction of heavy drinking days (e.g., >5 drinks/day) post-treatment, compared to pre-treatment.

Aim 3: To assess superiority of l-dlPFC iTBS to l-dlPFC cTBS to reduce opioid use in OUD patients post-treatment. Superiority will be assessed by evaluating 1) treatment engagement at the 4-week interval (e.g., number of prescribed OUD treatments addended); 2) reduction of opioids used post-treatment, compared to pre-treatment.

03

Conditions studied

  • Opioid Use
  • Alcohol Use Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be able to give valid in English.
  • Absence of cognitive impairment: IQ equivalent of ≥ 70 on the WRAT.
  • Receiving treatment for either AUD or OUD

Exclusion criteria

Exclusion Criteria:

  • History of any neurological disorder that would increase seizure risk from rTMS such as stroke, brain lesions, previous neurosurgery, any history of seizure or fainting episode of unknown cause, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than one month.
  • Current meeting withdrawal criteria for alcohol: AUD participants will not meet for alcohol withdrawal: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) ≤ 5.
  • First-degree family history of epilepsy or multiple sclerosis.
  • Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps or sensors, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object in the body that precludes rTMS administration.
  • Current use of anti- or pro-convulsive action.
  • Use of benzodiazepines in the last 48 hours prior to rTMS. Benzodiazepines are used during alcohol withdrawal management but then are discontinued prior to recruitment into the study. Therefore, rTMS eligible participants will not continue taking benzodiazepines.
  • Lifetime history of schizophrenia, bipolar disorder, mania.
  • History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke, or .
  • Pregnant or lactating women.
  • TMS .
  • Treatment center discharge date does not allow for scheduling of all 5 rTMS days
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    AUD

    Individuals receiving treatment from HHC for AUD. Participants will be asked to complete a battery of tasks at the prior to the first rTMS session and after the last rTMS session. Each rTMS eligible participant will be scheduled for 5 rTMS visits (to be completed within 2 weeks from start to finish). Each rTMS session will start with finding motor hotspot, the rTMS dose, then application of rTMS. Within AUD participants, random assignment of rTMS site (cTBS at mPFC vs iTBS at l-dlPFC) will occur in sets of 6 thus increasing rTMS site distribution even if a small sample is collected.

    Device: repetitive transcranial magnetic stimulation (rTMS) for AUD

  • Experimental
    OUD

    Individuals receiving treatment from HHC for OUD. Participants will be asked to complete a battery of tasks at the prior to the first rTMS session and after the last rTMS session. Each rTMS eligible participant will be scheduled for 5 rTMS visits (to be completed within 2 weeks from start to finish). Each rTMS session will start with finding motor hotspot, the rTMS dose, then application of rTMS. Within OUD participants, random assignment of rTMS type (cTBS vs iTBS ) applied to l-dlPFC will occur in sets of 6 thus increasing rTMS site distribution even if a small sample is collected.

    Device: repetitive transcranial magnetic stimulation (rTMS) for OUD

Interventions

  • Devicerepetitive transcranial magnetic stimulation (rTMS) for AUD

    Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted using standard EEG electrode locations: FP1 for mPFC and F3 for l-dlPFC.

  • Devicerepetitive transcranial magnetic stimulation (rTMS) for OUD

    Description: Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted using standard EEG electrode location F3 for l-dlPFC.

06

What researchers measure

Primary outcomes

  1. Number of participants that successfully complete the study

    Successful completion of the study is defined as completing the rTMS protocol and the 4-week post-treatment follow-up.

    Time frame: 4-weeks post-treatment

  2. Mean number of drinks per day

    A timeline follow-back will be used to assess number of drinks per day.

    Time frame: 4-weeks post-treatment

  3. Mean number of heavy drinking days

    A timeline follow-back will be used to assess number of heavy drinking days.

    Time frame: 4-weeks post-treatment

  4. Opioid use

    A timeline follow-back will be used to assess the quantity of opioids used in bags.

    Time frame: 4-weeks post-treatment

07

Study locations

1 site
  • Hartford Healthcare
    Hartford, Connecticut 06102, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Nov 2025, 6 months.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 6 months is below that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion May 2026 → Nov 2025 and completion May 2026 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 9, 2025
StartActual
May 12, 2025
Primary completionActual
Nov 24, 2025was May 2026
CompletionActual
Nov 24, 2025was May 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 29, 2026
Primary completion
May 2026→Nov 24, 2025 (actual)
Sep 29, 2026
Study completion
May 2026→Nov 24, 2025 (actual)
Sep 29, 2026
Enrollment
80 (estimated)→47 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Completed
    Primary completion May 2026→Nov 24, 2025 (now actual)
    Study completion May 2026→Nov 24, 2025 (now actual)
    Enrollment 80 (estimated)→47 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06963476
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
May 9, 2025
Start date
May 12, 2025
Primary completion
Nov 24, 2025
Completion
Nov 24, 2025
Last update
Sep 29, 2026

Study contacts

Vaughn R Steele, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion